Your browser doesn't support javascript.
loading
Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial.
Jiang, Z F; Cristofanilli, M; Shao, Z M; Tong, Z S; Song, E W; Wang, X J; Liao, N; Hu, X C; Liu, Y; Wang, Y; Zeng, L; Zhang, M.
Affiliation
  • Jiang ZF; Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
Ann Oncol ; 24(11): 2766-72, 2013 Nov.
Article in En | MEDLINE | ID: mdl-23857960
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptor, ErbB-2 / Triple Negative Breast Neoplasms / Neoplastic Cells, Circulating Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Country/Region as subject: Asia Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2013 Type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptor, ErbB-2 / Triple Negative Breast Neoplasms / Neoplastic Cells, Circulating Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Middle aged Country/Region as subject: Asia Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2013 Type: Article Affiliation country: China